Trial Profile

Prospective, Observational Trial Evaluating Xeomin (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botulinum-Toxin-A (Primary)
Indications Blepharospasm; Torticollis
Focus Therapeutic Use
Acronyms XCiDaBLE
Sponsors Merz Pharma

Most Recent Events

21 Apr 2016 Results comparing response patterns from ANCHOR-CD, CD-PROBE and XCiDaBLE studies, presented at the 68th Annual Meeting of the American Academy of Neurology
18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
25 Apr 2015 Final results from the cervical dystonia cohort (n=369) presented at the 67th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com